Bookmark

Add to MyYahoo RSS

Imclone Systems News

News on Imclone Systems (Ticker: LLY) continually updated from thousands of sources around the net.

Monday Apr 14 | AmericanBankingNews.com

Eli Lilly and Upgraded to "Hold" by Jefferies

The firm currently has a $54.00 target price on the stock, up from their previous target price of $45.00.

Comment?

Related Topix: Alnara Pharmaceuticals, Biotech, Food, Medicine, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Monday Apr 14 | AmericanBankingNews.com

Eli Lilly and PT Raised to $54.00

The firm currently has a "hold" rating on the stock. A number of other analysts have also recently weighed in on LLY.

Comment?

Related Topix: Alnara Pharmaceuticals, Biotech, Food, Medicine, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Fri Apr 11, 2014

Indianapolis Business News

Indianapolis court backs patent for Lilly cancer drug Alimta

A federal court has upheld the patent that protects Eli Lilly and Co.' s lung-cancer treatment from generic competition until 2022.

Comment?

Related Topix: Medicine, Cancer, Health, Alnara Pharmaceuticals, Biotech, Food, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Tue Apr 08, 2014

BioSpace

Verdict In: Jury Orders Takeda Pharmaceutical Co. Ltd., Eli Lilly and ...

Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Alnara Pharmaceuticals, Food, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation

Sun Apr 06, 2014

Indianapolis Business News

Indianapolis court backs patent for Lilly cancer drug Alimta

A federal court has upheld the patent that protects Eli Lilly and Co.' s lung-cancer treatment from generic competition until 2022.

Comment?

Related Topix: Medicine, Cancer, Health, Alnara Pharmaceuticals, Biotech, Food, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Thu Apr 03, 2014

AmericanBankingNews.com

Cowen & Company Upgrades Eli Lilly and to Outperform

The firm currently has a $68.00 price objective on the stock, up from their previous price objective of $61.00.

Comment?

Related Topix: Alnara Pharmaceuticals, Biotech, Food, Medicine, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Wed Apr 02, 2014

Indianapolis Business News

U.S. court backs patent for Lilly cancer drug Alimta

A federal court has upheld the patent that protects Eli Lilly and Co.' s lung-cancer treatment from generic competition until 2022.

Comment?

Related Topix: Medicine, Cancer, Health, Alnara Pharmaceuticals, Biotech, Food, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Eli Lilly, Healthcare Industry

Mon Mar 31, 2014

Wall Street Journal

Judge Upholds Validity of Eli Lilly Patent

A federal judge upheld the validity of a key U.S. patent for Eli Lilly & Co.' s blockbuster lung-cancer drug Alimta, a big legal victory that could relieve sales pressure for the drug maker later this decade.

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Alnara Pharmaceuticals, Food, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation

Fri Mar 28, 2014

Indianapolis Business News

Would-be Lilly competitor's inhaled insulin tied to lung concerns

MannKind Corp.'s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Biotech, MannKind, Diabetes, Health, Food and Drug Administration, Food, Agriculture, International Multifoods Corporation

Mon Mar 24, 2014

In-PharmaTechnologist.com

Lack of investment in production of low margin drugs behind shortages says expert

The thin profit margins associated with relatively simple sterile products has led to a reluctance to invest in operations and shortages, according to an industry expert.

Comment?

Related Topix: Food, Agriculture, International Multifoods Corporation, Pfizer, Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••